Immunological Backbone of Uveal Melanoma: Is There a Rationale for Immunotherapy?
Cancers (Basel)
; 11(8)2019 Jul 26.
Article
em En
| MEDLINE
| ID: mdl-31357439
ABSTRACT
No standard treatment has been established for metastatic uveal melanoma (mUM). Immunotherapy is commonly used for this disease even though UM has not been included in phase III clinical trials with checkpoint inhibitors. Unfortunately, only a minority of patients obtain a clinical benefit with immunotherapy. The immunological features of mUM were reviewed in order to understand if immunotherapy could still play a role for this disease.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Idioma:
En
Ano de publicação:
2019
Tipo de documento:
Article